Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Curran Healy, Ph.D.

Co-Author

This page shows the publications co-authored by Brian Healy and Charles Guttmann.
Connection Strength

3.850
  1. Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis. J Neurol Sci. 2009 Mar 15; 278(1-2):54-9.
    View in: PubMed
    Score: 0.422
  2. A novel classification of fatigue in multiple sclerosis based on longitudinal assessments. Mult Scler. 2020 05; 26(6):725-734.
    View in: PubMed
    Score: 0.227
  3. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.223
  4. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2020 11; 26(13):1708-1718.
    View in: PubMed
    Score: 0.220
  5. Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. J Neuroimaging. 2018 05; 28(3):273-277.
    View in: PubMed
    Score: 0.196
  6. Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. Mult Scler. 2018 07; 24(8):1105-1114.
    View in: PubMed
    Score: 0.189
  7. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.186
  8. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Mult Scler. 2016 12; 22(14):1841-1849.
    View in: PubMed
    Score: 0.173
  9. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. Neuroimage Clin. 2015; 8:606-10.
    View in: PubMed
    Score: 0.165
  10. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. Neuroimage. 2015 Oct 01; 119:81-8.
    View in: PubMed
    Score: 0.165
  11. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.123
  12. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am J Neuroradiol. 2011 Mar; 32(3):515-21.
    View in: PubMed
    Score: 0.122
  13. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
    View in: PubMed
    Score: 0.121
  14. Seasonal prevalence of MS disease activity. Neurology. 2010 Aug 31; 75(9):799-806.
    View in: PubMed
    Score: 0.118
  15. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.118
  16. Disease modeling in multiple sclerosis: assessment and quantification of sources of variability in brain parenchymal fraction measurements. Neuroimage. 2010 Oct 01; 52(4):1367-73.
    View in: PubMed
    Score: 0.115
  17. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. AJNR Am J Neuroradiol. 2009 Oct; 30(9):1731-9.
    View in: PubMed
    Score: 0.110
  18. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.109
  19. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
    View in: PubMed
    Score: 0.101
  20. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. J Neuroimaging. 2021 03; 31(2):388-393.
    View in: PubMed
    Score: 0.061
  21. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020 06; 7(6):945-955.
    View in: PubMed
    Score: 0.058
  22. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult Scler Relat Disord. 2017 Oct; 17:47-53.
    View in: PubMed
    Score: 0.047
  23. Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One. 2017; 12(4):e0174866.
    View in: PubMed
    Score: 0.047
  24. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.039
  25. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol. 2013 Nov 13; 13:173.
    View in: PubMed
    Score: 0.037
  26. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  27. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
    View in: PubMed
    Score: 0.036
  28. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.032
  29. A 3T MR imaging investigation of the topography of whole spinal cord atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2011 Jun-Jul; 32(6):1138-42.
    View in: PubMed
    Score: 0.031
  30. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.031
  31. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
    View in: PubMed
    Score: 0.030
  32. Brain regional lesion burden and impaired mobility in the elderly. Neurobiol Aging. 2011 Apr; 32(4):646-54.
    View in: PubMed
    Score: 0.027
  33. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. J Neurol Sci. 2009 Apr 15; 279(1-2):99-105.
    View in: PubMed
    Score: 0.027
  34. 3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis. Neuroimage. 2009 Jul 01; 46(3):633-41.
    View in: PubMed
    Score: 0.027
  35. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.026
  36. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.026
  37. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.